Integrin alpha4beta7 Inhibitors
3 drugsAbout Integrin alpha4beta7
Integrin alpha4beta7 (α4β7) is a cell surface receptor mediating leukocyte trafficking, especially to the gut, by binding to MAdCAM-1 on endothelial cells. This interaction facilitates immune cell adhesion and infiltration, driving inflammation in target tissues. α4β7 is thus a key player in immune responses.
α4β7 is a therapeutic target for modulating immune cell migration, though no genetic evidence directly links it to specific diseases. Blocking α4β7/MAdCAM-1 interaction reduces inflammation, making it relevant for autoimmune and inflammatory conditions.
Three FDA-approved drugs target α4β7: TYRUKO, ENTYVIO, and TYSABRI. These include antibody (2 drugs) and other biologic (1 drug) modalities, developed by Novartis, Takeda and Biogen, respectively, for CNS, immunology and other therapeutic areas.
Top Integrin alpha4beta7 Drugs
The competitive landscape includes Novartis, Takeda, and Biogen, each with an approved drug.
High concentration of approved drugs among three companies suggests significant barriers to entry.
Integrin alpha4beta7 Drug Modality Landscape
Modalities
Routes of Administration
Integrin alpha4beta7 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Consider novel modalities to differentiate from existing antibody-based therapies and capture market share.
📈 Modality Evolution
Antibodies pioneered Integrin alpha4beta7 targeting (2004), with other biologics entering more recently (2023).
Integrin alpha4beta7 Clinical Trials 129 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Integrin alpha4beta7. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 14 | 4 | 2 | 78% |
| Phase 2 | 29 | 14 | 6 | 9 | 70% |
| Phase 3 | 32 | 15 | 7 | 10 | 68% |
| Phase 4 | 48 | 23 | 12 | 13 | 66% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Integrin alpha4beta7 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Integrin alpha4beta7. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Integrin alpha4beta7 Drug Approval Timeline (2004 - 2023)
The approval timeline spans 20 years, from TYSABRI (2004) to TYRUKO (2023).
The recent approval of TYRUKO indicates continued interest and potential in targeting Integrin alpha4beta7.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 54 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Integrin alpha4beta7. A trial counts if an approved drug acting on Integrin alpha4beta7 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.